Precision Medicine: Solving the Mystery of Myocarditis in the Aftermath of SARS-CoV-2
- PMID: 37019562
- PMCID: PMC10069474
- DOI: 10.1016/j.jchf.2023.02.002
Precision Medicine: Solving the Mystery of Myocarditis in the Aftermath of SARS-CoV-2
Keywords: COVID-19; endomyocardial biopsy; myocarditis; precision medicine.
Conflict of interest statement
Funding Support and Author Disclosures Dr Feldman was the founder of and held equity in Renovacor Inc, a biotechnology company focused on gene therapy for patients with rare inherited cardiovascular disease that licensed a BAG3 portfolio of patents from Temple University. Renovacor was recently purchased by Rocket Pharmaceuticals and Rocket now funds work ongoing in the Feldman laboratory. No funds from Renovacor or Rocket Inc were used in the preparation of this paper. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
